文献速递乳房整形与再造

系统综述:乳腺癌结局中脂肪移植重建的肿瘤学安全性

Systematic review: Oncological safety of reconstruction with fat grafting in breast cancer outcomes.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2022-08-24

本系统综述纳入11项研究、共5886例患者,评估自体脂肪移植(AFG)用于乳腺癌术后乳房重建的肿瘤学安全性。汇总分析显示AFG与局部区域复发(LRR)和无病生存期(DFS)风险增加无关,LRR的汇总风险比为1.26(95%CI 0.90-1.76),DFS的汇总风险比为1.27(95%CI 0.96-1.69)。作者认为AFG可安全用于乳腺癌术后乳房重建,但仍需随机对照试验及1级循证医学证据来巩固结论。

要点

  • 纳入11项研究共5886例患者,7项报告LRR、5项报告DFS。
  • AFG与LRR风险增加无关,汇总HR为1.26(95%CI 0.90-1.76)。
  • AFG与DFS风险增加无关,汇总HR为1.27(95%CI 0.96-1.69)。

核心结论

  • AFG可安全用于乳腺癌术后乳房重建。
  • 仍需随机对照试验、相关系统综述及1级循证医学研究来巩固本系统综述所纳入研究的结论。

研究设计与样本

  • 系统综述,检索PubMed、MEDLINE、Embase、PreMEDLINE、Ebase、CINAHL、PsycINFO、Clinicaltrials.gov、Scopus和Cochrane数据库。
  • 方案按PRISMA-P指南制定,纳入研究须符合基于PICOS方法预设的标准。
  • 共纳入11项研究;7项研究报告LRR,5项研究报告DFS,共5886例患者。

主要发现

  • AFG与LRR增加无关,汇总HR为1.26(95%CI 0.90-1.76)。
  • AFG与DFS增加无关,汇总HR为1.27(95%CI 0.96-1.69)。

关键数值与推荐

  • LRR汇总HR为1.26(95%CI 0.90-1.76)。
  • DFS汇总HR为1.27(95%CI 0.96-1.69)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。
  • 作者指出仍需随机对照试验、相关系统综述及1级循证医学研究来巩固结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autologous fat grafting (AFG) has become a commonly used procedure for breast reconstruction (BR) after cancer removal. Nevertheless, oncological considerations remain for AFG after breast cancer surgery. OBJECTIVES: This article aims to evaluate the oncological safety of AFG in BR and its effect on disease-free survival (DFS) and local-regional recurrences (LRR). METHODS: A systematic review regarding the use of AFG in BR to identify a difference in incidence rates of LRR and DFS between patients who had AFG and controls was performed using PubMed, MEDLINE, Embase, PreMEDLINE, Ebase, CINAHL, PsycINFO, Clinicaltrials.gov, Scopus, and Cochrane databases. The protocol was developed following the Preferred Reporting for Items for Systematic Reviews-Protocols (PRISMA-P) guidelines. The included studies had to match predetermined criteria according to the PICOS approach. RESULTS: A total of 11 studies were included. Seven studies reported LRR, and 5 studies reported DFS in 5,886 patients. Our systematic review showed that AFG was not associated with increased LRR and DFS. Pooled hazard ratios (HRs) (95% confidence intervals [CIs]) for LRR and DFS were 1.26 (0.90-1.76) and 1.27 (0.96-1.69), respectively. CONCLUSIONS: AFG can, therefore, be performed safely in BR after breast cancer. Further, randomized controlled trials and related systematic reviews, as well as evidence-based medicine (EBM) studies of level 1, are required to consolidate the results of the studies identified in this systematic review.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Gentile P, Cervelli V. Systematic review: Oncological safety of reconstruction with fat grafting in breast cancer outcomes. J Plast Reconstr Aesthet Surg. 2022. PMID: 36180337. doi:10.1016/j.bjps.2022.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。